European Medicines Agency will review Pfizer’s Marketing Authorization Application for XELJANZ
Pfizer has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for XELJANZ (tofacitinib citrate) for review. Read More »